SAN FRANCISCO, August 06, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ...

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated.

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

Florida Governor Ron DeSantis shared some sharp criticism of the H-1B visa program, even as Trump maintains legal immigration levels.

New quantum computing system allows multiple users to run programs simultaneously using virtual machines.

Action News Jax’s Ben Becker has learned that the company now operating the Jacksonville Housing Authority’s Housing Choice Voucher Program is under federal scrutiny.

Analyst David Pollack pinpoints which college football team has the best running back room in the nation.